TGF-beta-treated antigen presenting cells suppress collagen-induced arthritis through the promotion of Th2 responses
Experimental & Molecular Medicine
;
: 187-194, 2010.
Article
in English
| WPRIM
| ID: wpr-203594
ABSTRACT
Collagen-induced arthritis (CIA) is mediated by self-reactive CD4+ T cells that produce inflammatory cytokines. TGF-beta2-treated tolerogenic antigen-presenting cells (Tol-APCs) are known to induce tolerance in various autoimmune diseases. In this study, we investigated whether collagen-specific Tol-APCs could induce suppression of CIA. We observed that Tol-APCs could suppress the development and severity of CIA and delay the onset of CIA. Treatment of Tol-APCs reduced the number of IFN-gamma- and IL-17-producing CD4+ T cells and increased IL-4- and IL-5-producing CD4+ T cells upon collagen antigen stimulation in vitro. The suppression of CIA conferred by Tol-APCs correlated with their ability to selectively induce IL-10 production. We also observed that treatment of Tol-APCs inhibited not only cellular immune responses but also humoral immune responses in the process of CIA. Our results suggest that in vitro-generated Tol-APCs have potential therapeutic value for the treatment of rheumatoid arthritis as well as other autoimmune diseases.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Arthritis, Experimental
/
Chickens
/
Ovalbumin
/
Th2 Cells
/
Th1 Cells
/
Collagen Type II
/
Transforming Growth Factor beta2
/
Immune Tolerance
/
Mice, Inbred BALB C
/
Antigen-Presenting Cells
Limits:
Animals
Language:
English
Journal:
Experimental & Molecular Medicine
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS